INFORMATION DISCLOSURE STATEMENT BY APPLICANT

MAR 0 9 2007

Attorney Docket Number	7572-74818-01
Application Number	10/576,988
Filing Date	April 20, 2006
First Named Inventor	Rodriguez Aguirre
Art Unit	1645
Examiner Name	Not yet assigned

U.S. RAPENT DOCUMENTS

Copies of U.S. Patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date.

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee
		2002/0165176	November 7, 2002	HAYNES et al.
		2003/0152592	August 14, 2003	BOOT et al.
		2003/0175301	September 18, 2003	COHEN et al.
-		2004/0005338	January 8, 2004	BACHMANN et al.
	1	2004/0116664	June 17, 2004	DE FILETTE et al.
		2004/0223976	November 11, 2004	BIANCHI et al.
		2005/0003349	January 6, 2005	KAWAOKA
		2005/0009008	January 13, 2005	ROBINSON et al.
		2005/0186621	August 25, 2005	GALARZA et al.
		2006/0024670	February 2, 2006	LUKE et al.
		2006/0251623	November 9, 2006	BACHMANN et al.
		2006/0121468	June 8, 2006	ALLNUTT et al.
		2006/0121567	June 8, 2006	VAKHARIA
		5,290,686	March 1, 1994	KENDAL et al.
		5,605,827	February 25, 1997	JACKWOOD et al.
		5,605,792	February 25, 1997	JACKWOOD et al.
		5,614,409	March 25, 1997	AZAD et al.

EXAMINER	DATE
SIGNATURE:	CONSIDERED:
SIGNATURE.	COTTOIDE/CED.

^{*} Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE SPATEMENT
/ 20 \
BY APPLICANT 9:\
14AD A Q 2007

MAR 0 9 2007

Attorney Docket Number	7572-74818-01
Application Number	10/576,988
Filing Date	April 20, 2006
First Named Inventor	Rodriguez Aguirre
Art Unit	1645
Examiner Name	Not yet assigned

 		or realite Therefore assigned
5,616,327	** RADE POINT 1, 1997	JUDD et al.
5,641,490	June 24, 1997	PAOLETTI et al.
5,658,572	August 19, 1997	PAOLETTI et al.
5,788,970	August 4, 1998	VAKHARIA et al.
5,871,744	February 16, 1999	VAKHARIA et al.
 5,916,879	June 29, 1999	WEBSTER
5,932,426	August 3, 1999	BARALLE et al.
6,017,759	January 25, 2000	VAKHARIA et al.
6,114,112	September 5, 2000	JACKWOOD
6,156,314	December 5, 2000	VAKHARIA et al.
6,169,175	January 2, 2001	FRACE et al.
6,231,868	May 15, 2001	VAKHARIA et al.
6,274,147	August 14, 2001	VAKHARIA et al.
6,406,843	June 18, 2002	SKEELES and NEWBERRY
6,458,362	October 1, 2002	CASAL et al.
6,528,063	March 4, 2003	STRAM et al.
6,596,280	July 22, 2003	VAKHARIA et al.
6,602,705	August 5, 2003	BARNETT et al.
6,764,684	July 20, 2004	SAITOH et al.
6,872,395	March 29, 2005	KAWAOKA
		<u> </u>

EXAMINER	DATE
SIGNATURE:	CONSIDERED:
DIGITALI OICE.	CONDIDITION.

^{*} Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STAT BY APPLICANT MAR **0 9**,2007

Attorney Docket Number	7572-74818-01	
Application Number	10/576,988	
Filing Date	April 20, 2006	
First Named Inventor	Rodriguez Aguirre	
Art Unit	1645	
Examiner Name	Not yet assigned	

6,936,256	gust 30, 2005	VAKHARIA	
6,964,769	November 15, 2005	SEBBEL et al.	
7,022,327	April 4, 2006	LÜTTICKEN et al.	

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee
		EPC	EP 0 861 665 A1	September 2, 1998	Dimminaco AG/SA/LTD.
		EPC	EP 0 887 412 B1	December 30, 1998	Akzo Nobel NV
}		EPC	EP 1 069 187 A1	January 17, 2001	Stichting Dienst Landbouwkundig Onderzoeck
		EPC	EP 1 621 612 A1	February 1, 2006	Bionostra, S.L. and Consejo Superior de Investigaciones Científicas
		Japan	5194597A	August 3, 1993	Nippon Seibutsu Kagaku Kenkyus
		WIPO	WO 93/03145 A1	February 18, 1993	Virogenetics Corporation
		WIPO	WO 95/26196 A1	October 5, 1995	The University of Maryland College Park
		WIPO	WO 98/09646 A1	March 12, 1998	University of Maryland Biotechnology Institute
		WIPO	WO 98/33522 A1	August 6, 1998	Dimminaco AG
		WIPO	WO 98/50071 A1	November 12, 1998	Chiron Corporation
		WIPO	WO 99/16866 A1	April 8, 1999	University of Maryland Biotechnology Institute
		WIPO	WO 00/37649 A2	June 29, 2000	University of Maryland Biotechnology Institute
	4	WIPO	WO 01/97839 A1	December 27, 2001	Meristem
		WIPO	WO 02/00885 A2	January 3, 2002	American Cyanamid Company
EXAMINER SIGNATUR				DATE CONSIDERED:	

^{*} Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

3

INFORMATION DISCLOSURE S	TAPEMENT.
BY APPLICANT	

MAR 0 9 2007

Attorney Docket Number	7572-74818-01
Application Number	10/576,988
Filing Date	April 20, 2006
First Named Inventor	Rodriguez Aguirre
Art Unit	1645
Examiner Name	Not yet assigned

	The second secon	Examiner Name	Not yet assigned
WIPO	WO 02/088339	November 7, 2002	Institut National de la Recherche Agronomique (INRA)
WIPO	WO 02/096940 A2	December 5, 2002	ID-Lelystad, Institut Voor Dierhouderij En Diergezondheid B.V.
WIPO	WO 03/013597 A1	February 20, 2003	University of Maryland Biotechnology Institute
WIPO	WO 03/024480 A2	March 27, 2003	Cytos Biotechnology AG
WIPO	WO 03/024481 A2	March 27, 2003	Cytos Biotechnology AG
WIPO	WO 03/074552 A1	September 12, 2003	Akzo Nobel N.V.
WIPO	WO 2004/003143 A2	January 8, 2004	Allnutt and Kyle
WIPO	WO 2004/007538 A2	January 22, 2004	Cytos Biotechnology AG
WIPO	WO 2004/025263 A2	March 25, 2004	Advanced Bionutrition Corporation
WIPO	WO 2004/087900 A1	October 14, 2004	Consejo Superior de Investigaciones Científicas and Bionostra, S.L.
WIPO	WO 2005/049794 A2	June 2, 2005	University of Georgia Research Foundation, Inc.
WIPO	WO 2005/071069 A1	August 4, 2005	Consejo Superior de Investigaciones Científicas and Bionostra, S.L.
WIPO	WO 2005/105834 A1	November 10, 2005	Consejo Superior de Investigaciones Científicas and Bionostra, S.L.
WIPO	WO 2006/027698 A1	March 16, 2006	Chiron Behring Gmbh & Co.
WIPO	WO 2006/032674 A1	March 30, 2006	Cytos Biotechnology AG

EXAMINER	DATE
SIGNATURE:	CONSIDERED:
biotyri ords.	CONSIDERED.

^{*} Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

MAR 0 9 2007

Attorney Docket Number	7572-74818-01
Application Number	10/576,988
Filing Date	April 20, 2006
First Named Inventor	Rodriguez Aguirre
Art Unit	1645
Examiner Name	Not yet assigned

Examiner's Initials*	Cite No. (optional)	OTHER DOCUMENTS
:		BIRGHAN et al., "A non-canonical lon proteinase lacking the ATPase domain employs
		the Ser-Lys catalytic dyad to exercise broad control over the life cycle of a double-
		stranded RNA virus," <i>Embo J.</i> , 19:114-123, 2000.
		BÖTTCHER et al., "Three-dimensional structure of infectious bursal disease virus
		determined by electron cryomicroscopy," J. Virol., 71:325-330, 1997.
		CASTÓN et al., "C terminus of infectious bursal disease virus major capsid protein VP2
		is involved in definition of the T number for capsid assembly," J. Virol., 75:10815-10828,
		2001.
		CHEVALIER et al., "The maturation process of pVP2 requires assembly of infectious
:		bursal disease virus capsids," J. Virol., 76:2384-2392, 2002.
	-,,	CHEVALIER et al., "The last C-terminal residue of VP3, glutamic acid 257, controls
		capsid assembly of infectious bursal disease virus," J. Virol., 78:3296–3303, 2004.
		CHUNG et al., "Sequence analysis of the bicistronic Drosophila X virus genome segment
		A and its encoded polypeptides," Virology, 225:359-368, 1996.
		DA COSTA et al., "The capsid of infectious bursal disease virus contains several small
		peptides arising from the maturation process of pVP2," J. Virol., 76:2393-2402, 2002.
1		DA COSTA et al., "Blotched snakehead virus is a new aquatic birnavirus that is slightly
		more related to avibirnavirus than to aquabirnavirus," J. Virol., 77:719-725, 2003.
		FERNÁNDEZ-ARIAS et al., "Expression of ORF A1 of infectious bursal disease virus
		results in the formation of virus-like particles," J. Gen. Virol., 79:1047-1054, 1998.
		FERNÁNDEZ-ARIAS et al., "The major antigenic protein of infectious bursal disease
		virus, VP2, is an apoptotic inducer," <i>J. Virol.</i> , 71:8014-8018, 1997.
		GALARZA et al., "Virus-like particle (VLP) vaccine conferred complete protection
		against a lethal influenza virus challenge," Viral. Immunol., 18:365-372, 2005.
		HU et al., "Chimeric infectious bursal disease virus-like particles expressed in insect cells
		and purified by immobilized metal affinity chromatography," Biotechnol. Bioeng.,
		63:721-729, 1999.
- -		HU and BENTLEY, "Effect of MOI ratio on the composition and yield of chimeric
		infectious bursal disease virus-like particles by baculovirus co-infection: deterministic
		predictions and experimental results," Biotechnol. Bioeng. 75:104-119, 2001.
		IONESCU et al., "Pharmaceutical and immunological evaluation of human
		papillomavirus viruslike particle as an antigen carrier," J. Pharm. Sci., 95:70-79, 2006.
		JAGADISH et al., "Expression and characterization of infectious bursal disease virus
		polyprotein in yeast," Gene, 95:179-186, 1990.

EXAMINER D.	DATE
SIGNATURE: CO	CONSIDERED:

^{*} Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

SLR/dm 03/05/07 7572-74818-01 636429.doc P1392PC00	Attorney Docket Number	7572-74818-01
	Application Number	10/576,988
INFORMATION DISCLOSURE STATEMENT	Filing Date	April 20, 2006
BY APPLICANT (%)	First Named Inventor	Rodriguez Aguirre
MAR 0 9 2007	Art Unit	1645
	Examiner Name	Not yet assigned
JEGERLEHNER et al., La función A weak protection mediated via antibo 172:5598-5605, 2004.	dy-dependent NK cell activit	ty," J. Immunol.
KADONO-OKUDA et al., "Baculov hormone in larvae of the silkworm, I 213:389-396, 1995. KATAGIRI and INGHAM, "Enhance	Bombyx mori." Biochem. Bio	phys. Res. Commun.,
baculovirus expression system by ad 2002.	ldition of secretion signal," B	Riotechniques, 33:24-26,
KIBENGE et al., "Formation of virus A) of infectious bursal disease virus 63:49-55, 1999.	-	• • • • •
KINGSMAN et al., "Yeast retrotran Y. Acad. Sci., 754:202-213, 1995.		
KOCHAN et al., "Characterization of IBDV," Arch. Virol., 148:	723-744, 2003.	
LEJAL et al., "Role of Ser-652 and I disease virus VP4 and identification 992, 2000.	•	-
LEONG et al. (Eds.), "Virus Taxono Seventh Report of International Com San Diego, pp. 481–490, 2000.		
LEUSCH et al., "A novel host-vecto baculoviruses (bacmids) in Escheric	•	
LO-MAN, et al., "A recombinant vin efficient antigen carrier to elicit a po J. Immunol., 28:1401-1407, 1998.		
LOMBARDO et al., "VP1, the putate bursal disease virus, forms complexe encapsidation into virus-like particle	es with the capsid protein VP	3, leading to efficient
LOMBARDO et al., "VP5, the nons virus, accumulates within the host pl 277:345-357, 2000.	1 71 1	
LUCKOW et al., "Efficient generation specific transposon-mediated insertion propagated in Escherichia coli.," J.	n of foreign genes into a bact	

EXAMINER	DATE
SIGNATURE:	CONSIDERED:

^{*} Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
MAR 0 9 2007

Attorney Docket Number	7572-74818-01
Application Number	10/576,988
Filing Date	April 20, 2006
First Named Inventor	Rodriguez Aguirre
Art Unit	1645
Examiner Name	Not yet assigned

Examiner Name Not yet assigned
MACREADIE et al. protection against infectious bursal disease virus by viral
VP2 expressed in yeast," Vaccine, 8:549-552, 1990.
MARAVER et al., "Identification and molecular characterization of the RNA polymerase-
binding motif of the inner capsid protein VP3 of infectious bursal disease virus," J. Virol.,
77:2459-2468, 2003.
MARAVER et al., "The Oligomerization Domain of VP3, the Scaffolding Protein of
Infectious Bursal Disease Virus, Plays a Critical Role in Capsid Assembly," J. Virol.,
77:6438–6449, 2003.
MARTÍNEZ-TORRECUADRADA et al., "Different architectures in the assembly of
infectious bursal disease virus capsid protein expressed in insect cells," Virology,
278:322-331, 2000.
MARTÍNEZ-TORRECUADRADA et al., "Structure-dependent efficacy of infectious
bursal disease virus (IBDV) recombinant vaccines," <i>Vaccine</i> , 21:3342-3350, 2003.
OÑA et al., "The C-terminal domain of the pVP2 precursor is essential for the interaction
between VP2 and VP3, the capsid polypeptides of infectious bursal disease virus,"
Virology, 322:135-142, 2004.
PITCOVSKI et al., "Development and large-scale use of recombinant VP2 vaccine for the
prevention of infectious bursal disease of chickens," <i>Vaccine</i> , 21:4736-4743, 2003.
POUS et al., "Structure of birnavirus-like particles determined by combined electron cryomicroscopy and X-ray crystallography," J. Gen. Virol., 86:2339–2346, 2005.
QIU et al., "Expression and characterization of virus-like particles containing rubella virus
structural proteins," J. Virol., 68:4086-4091, 1994.
RAZZINI et al., "Low-density lipoprotein (LDL) receptor/transferrin fusion protein: in
vivo production and functional evaluation as a potential therapeutic tool for lowering
plasma LDL cholesterol.," Hum. Gene Ther., 15:533-541, 2004.
SÁNCHEZ and RODRÍGUEZ, "Proteolytic processing in infectious bursal disease virus:
identification of the polyprotein cleavage sites by site-directed mutagenesis," Virology,
262:190-199, 1999.
SCHMIDT et al., "Binding of external ligands onto an engineered virus capsid.," Protein
Eng., 14:769-774, 2001.
SHARMA et al., "Infectious bursal disease virus of chickens: pathogenesis and
immunosuppression," Dev. Comp. Immunol., 24:223-235, 2000.
SHIN and FOLK, "Formation of polyomavirus-like particles with different infectious
bursal disease virus, plays a critical role for capsid formation," J. Virol., 77:11491-11498,
2003.
SHIVAPPA et al., "Development of a subunit vaccine for infectious pancreatic necrosis
virus using a baculovirus insect/larvae system," Dev. Biol. (Basel), 121:165-174, 2005.

EXAMINER	DATE
SIGNATURE:	CONSIDERED:

^{*} Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT
MAR 0 9 2007

Attorney Docket Number	7572-74818-01
Application Number	10/576,988
Filing Date	April 20, 2006
First Named Inventor	Rodriguez Aguirre
Art Unit	1645
Examiner Name	Not yet assigned

MAR 0 9 2007 9	Art Unit	1645
	Examiner Name	Not yet assigned
TACKEN et al., "Interactions in viv virus: capsid protein VP3 intereacts Gen. Virol., 81:209-218, 2000.	o between the proteins with the RNA-depende	of infectious bursal disease ent RNA polymerase, VP1," J.
VAKHARIA et al., "Infectious bursal disease virus structural proteins expressed in a baculovirus recombinant confer protection in chickens," J. Gen. Virol., 74:1201-1206, 1993.		
VAKHARIA, "Development of reconsiderated Biotechnol. Ann. Rev., 3:151-168, 19		nst infectious bursal disease,"
VAN DEN BERG et al., "Infectious 19:527-543, 2000.	TOTAL TOTAL CONTRACTOR OF THE	oro disease)," Rev. Sci. Tech.,
VEENENDAAL et al., "In vitro and fusion toxin targeting the neovascula 99:7866-7871, 2002.		
WANG et al., "Self-assembly of the expressed in insect cells and purification immobilized metal-ion affinity chronical expression and purification immobilized metal-ion affinity chronical expression."	ation of immunogenic c	chimeric rVP2H particles by
YAO and VAKHARIA, "Generation cDNA," J. Virol., 72:8913-8920, 19	n of infectious pancreat	
		·

EXAMINER	DATE CONSIDERED:
SIGNATURE:	CONSIDERED:

^{*} Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.